Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong ...Middle East

PR Newswire - News
HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted the marketing authorization application for ritonavir (100 mg film-coated tablet) in the Hong Kong Special Administrative Region of the People's Republic of...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong )

Apple Storegoogle play

Also on site :